Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 19 2013
Print RSS Feed

Breaking News

Related Searches:
Patheon, BSP Enter Cyto-Pact

July 3, 2008
Patheon has entered a sales and marketing agreement with Italy's BSP Pharmaceuticals, a developer and manufacturer of cytotoxic pharmaceutical products. Patheon will promote BSP's cytotoxic manufacturing capacity and development services and Aldo Bra…  Read More »
Bayer Acquires Maxygen’s Hemophilia Program

July 3, 2008
Bayer HealthCare will acquire Maxygen’s hemophilia program assets, including next-generation recombinant Factor VIIa protein MAXY-VII, the company's lead candidate, which is expected to enter Phase I trials in 3Q08. The total transaction is val…  Read More »
Akorn, Bioniche Enter Manufacturing Pact

July 3, 2008
Akorn, Inc. and Bioniche Pharma have entered into a five-year commercial manufacturing and supply agreement for two undisclosed pharmaceutical products. Under the terms of the agreement, Akorn will be responsible for the manufacturing and supply of t…  Read More »
Catalent, One World Team Up for Compliance Packaging

July 2, 2008
Catalent Pharma Solutions has entered into a joint marketing and collaboration agreement with One World Design and Manufacturing Group. Under the terms of the agreement, both companies will market One World's NextBottleT unit-dose compliance bottle t…  Read More »
Altea, Hospira To Develop Transdermal Product

July 2, 2008
Altea Therapeutics has entered into a partnership with Hospira for the development and commercialization of an undisclosed product using its PassPort Transdermal Delivery System. Under the terms of the agreement, Hospira has exclusive worldwide right…  Read More »
Symbio Adds Phase I Capabilities

July 2, 2008
Symbio LLC has opened a new Phase I clinical unit in Michigan City, IN. Symbio provides clinical trial management, biometrics, consulting, product development and topical formulation development. With the addition of the Phase I Unit, the company can…  Read More »
BASi Sells Phase I Unit

July 1, 2008
Bioanalytical Systems, Inc. (BASi) has sold its Baltimore Clinical Pharmacology Research Unit to a subsidiary of Algorithme Pharma Holdings, Inc. for $850,000 in cash, exiting the Phase I market.     Algorithme, based in Montreal, i…  Read More »
AZ, Palatin Amend R&D Pact

July 1, 2008
AstraZeneca and Palatin have amended their January 2007 global licensing and research agreement to discover, develop and commercialize compounds targeting melanocortin receptors.     Under the amendment, Palatin has agreed to licen…  Read More »
Genmab Reaches GSK MAb Milestone

July 1, 2008
Genmab has reached a development milestone for ofatumumab (HuMax-CD20) under the terms of its collaboration with GlaxoSmithKline. The milestone triggers a $6 million payment to Genmab as a result of the first patient treated in the Phase II study of…  Read More »
Galapagos Signs Management Pact with Sepracor

June 30, 2008
Galapagos NV's service division, BioFocus DPI, will provide compound management and related services to Sepracor for a total contract value of $1.5 million. Under the terms of the agreement, BioFocus DPI will receive, register, and store selected com…  Read More »
Covidien

June 30, 2008
Michael J. Giuliani, M.D. has been appointed vice president of R&D for Covidien's Pharmaceutical Products and Imaging Solutions. He will lead the R&D organization's efforts to identify and deliver advancements to the pharmaceutical and imagin…  Read More »
GSK Responds to FDA Inquiry for Cervarix

June 30, 2008
GlaxoSmithKline has submitted its response to questions raised by the FDA regarding its application for approval of Cervarix, its vaccine to prevent cervical cancer.     GSK will also submit Phase III efficacy study data from HPV-00…  Read More »
Schering-Plough, Merck End Respiratory JV

June 27, 2008
Schering-Plough and Merck withdrew the NDA for the Claritin (loratadine)/Singulair (montelukast) combination tablet. The companies also terminated the their respiratory joint venture formed in May 2000. The FDA issued a not-approvable letter in April…  Read More »
Exelixis, GSK Conclude Successful Pact

June 27, 2008
Exelixis and GlaxoSmithKline will end their six-year collaboration based on its success, on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select two compounds for further development and commercialization.…  Read More »
Centocor Submits Golimumab BLA

June 27, 2008
Centocor's BLA has been submitted to the FDA requesting approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis. Golimumab is the c…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: